One promising inhibitor is CCS1477, a CBP/p300 bromodomain inhibitor developed by CellCentric, which is currently in phase 1b/2a clinical trials for treating hematological malignancies and late-stage castration-resistant prostate cancer. This evidence concerns the gene EP300 and prostate carcinoma.